Bill And Melinda Gates Foundation Bill And Melinda Gates Foundation [Member] Bill And Melinda Gates Foundation [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Deferred license revenue Increase (Decrease) in Contract with Customer, Liability Leased Properties Lessee, Operating Leases [Text Block] Document Type Document Type Other income Other Nonoperating Income (Expense) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Commencement period for stage two upon achievement of stage one Commencement Period For Stage Two Upon Achievement Of Stage One Commencement Period For Stage Two Upon Achievement Of Stage One Related Party Related Party [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Proceeds from the exercise of stock options Proceeds from Issuance or Sale of Equity Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Receivables [Abstract] Receivables [Abstract] Minimum Minimum [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Leases Lessee, Leases [Policy Text Block] Other Current Assets Other Current Assets [Member] Current portion of lease liabilities Operating Lease, Liability, Current Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Warrant exercises, gross Proceeds from Warrant Exercises Licensing Agreements Licensing Agreements [Member] Statistical Measurement Statistical Measurement [Domain] Liabilities and stockholders’ equity (deficit) Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Additional potential grant funding Additional Potential Funding Related To Grant Award Additional Potential Funding Related To Grant Award Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Warrants exercised (in shares) Number Of Common Stock Warrants Exercised Number of common stock warrants exercised. Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Square footage of office space Net Rentable Area Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Obligation to purchase common stock Purchase Obligation Summary of Stock Option Activity for Amended 2014 Plan and Related Information Share-based Payment Arrangement, Option, Activity [Table Text Block] License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Amended and Restated Two Thousand Fourteen Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Milestone payments, contingent amount Milestone Payments Contingent Amount Milestone payments, contingent amount. Loss from operations Operating Income (Loss) Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Total current liabilities Liabilities, Current Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Subsequent Event Type Subsequent Event Type [Domain] Hammock Pharmaceuticals, Inc Hammock Pharmaceuticals, Inc. [Member] Hammock Pharmaceuticals, Inc. [Member] Class of Warrant or Right Class of Warrant or Right [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Commitments and contingencies (Note 7) Commitments and Contingencies Grant Grant [Member] Assets Assets [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Adare Adare Pharmaceuticals [Member] Adare Pharmaceuticals [Member] Entity Address, State or Province Entity Address, State or Province Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Cash paid for measurement of operating lease liabilities Operating Lease, Payments Accounts payable Accounts Payable, Current Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Research and development Research and Development Expense [Member] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Right of use asset Operating Lease, Right-of-Use Asset Proceeds from the exercise of common stock warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Gain on extinguishment of note payable Gain on extinguishment of notes payable and accrued interest Gain (Loss) on Extinguishment of Debt Potential annual license maintenance fee, payments in year one Potential Annual License Maintenance Fee, Payments In Year One Potential Annual License Maintenance Fee, Payments In Year One 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Stock options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Sale of Stock Sale of Stock [Axis] Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Entity Address, Postal Zip Code Entity Address, Postal Zip Code Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued Exchange cap (in shares) Common Stock, Exchange Cap Common Stock, Exchange Cap Total operating expenses Operating Expenses Document Transition Report Document Transition Report Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Cash and cash equivalents Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Current portion of contingent consideration Business Combination, Contingent Consideration, Liability, Current Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Warrants Warrant [Member] Shares underlying outstanding warrants (in shares) Class of Warrant or Right, Outstanding Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Warrant, exercise price, decrease (in usd per share) Warrant, Exercise Price, Decrease Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Level 2 Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report Revenue from grant for notice of award Revenue from Contract with Customer, Excluding Assessed Tax Regular purchase, common stock issuable (in shares) (up to) Regular Repurchase, Common Stock Issuable Regular Repurchase, Common Stock Issuable Canceled/forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Measurement Frequency [Domain] Measurement Frequency [Domain] Closing price of the Company's common stock (in usd per share) Share Price Equity [Abstract] Equity [Abstract] General and administrative General and Administrative Expense [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Annual percentage increase in outstanding number of common stock Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Business Acquisition Business Acquisition [Axis] Subsequent Event [Line Items] Subsequent Event [Line Items] Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Statement [Line Items] Statement [Line Items] Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Warrants Expiring on December 1, 2021 Warrants Expiring On December One Two Thousand Twenty One [Member] Warrants expiring on december one two thousand twenty one. Class of Stock [Domain] Class of Stock [Domain] Certain clinical and regulatory development milestone payments License Agreement Notice Period Of Termination License Agreement Notice Period Of Termination Expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Number of operating segments Number of Operating Segments Entity File Number Entity File Number Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Statement [Table] Statement [Table] Expiration Date Class Of Warrant Or Rights Warrants Expiration Date Class of warrant or rights warrants expiration date. Statistical Measurement Statistical Measurement [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Percentage of royalty rate Percentage Of Royalty Rate Percentage of royalty rate. Issuance of common stock from the exercise of warrants Adjustments to Additional Paid in Capital, Warrant Issued Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Regular purchase, common stock issuable, increase amount (in shares) Regular Purchase, Common Stock Issuable, Increase Amount Regular Purchase, Common Stock Issuable, Increase Amount Stock-based compensation expense Share-based Payment Arrangement, Expense Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Increase in number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Counterparty Name [Axis] Counterparty Name [Axis] Common stock, $0.0001 par value; 120,000,000 shares authorized; 47,312,822 and 41,596,253 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Grant, DARE-FRT1 Grant, DARE-FRT1 [Member] Grant, DARE-FRT1 Loss per common share - basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Unamortized stock-based compensation expense Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Entity Small Business Entity Small Business Document Fiscal Year Focus Document Fiscal Year Focus Unamortized costs related to legal, accounting, and other fees Deferred Offering Costs, Unamortized Portion Deferred Offering Costs, Unamortized Portion Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock And Warrants Net proceeds from issuance of common stock and warrants. Entity Current Reporting Status Entity Current Reporting Status Stock sale price (in usd per share) Sale of Stock, Price Per Share Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Prepaid expenses Prepaid Expense, Current Aggregate net proceeds on sales of shares of common stock Proceeds from Issuance of Common Stock Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Amendment Flag Amendment Flag Subsequent Event [Table] Subsequent Event [Table] Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Warrants Expiring on December 6, 2021 Warrants Expiring On December Six Two Thousand Twenty One [Member] Warrants expiring on december six two thousand twenty one. Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Business acquisition transaction value Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Options to purchase number of outstanding shares of common stock Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Aggregate commission rate Percentage Of Aggregate Commission Percentage of aggregate commission. Business combination shares issued (in usd per share) Business Acquisition, Share Price License agreement termination periodic discontinued sale of product License Agreement Termination Periodic Discontinued Sale Of Product License Agreement Termination Periodic Discontinued Sale Of Product Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current Other non-current assets Increase Decrease In Other Non Current Assets And Deferred Charges Increase decrease in other non-current assets and deferred charges. License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Purchase Agreement Purchase Agreement [Member] Purchase Agreement Upon Signing of Development and Option Agreement Upon Signing Of Development And Option Agreement [Member] Upon Signing Of Development And Option Agreement [Member] Total operating lease liabilities Operating Lease, Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Related Party Related Party [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Project [Domain] Project [Domain] Total stockholders' equity (deficit) Beginning balance Ending balance Stockholders' Equity Attributable to Parent Offering expenses Payments of Stock Issuance Costs Total liabilities and stockholders' equity (deficit) Liabilities and Equity Common stock issued to microchips capital stock holders (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Address, City or Town Entity Address, City or Town Subsequent Events Subsequent Events [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Non-cash lease expenses Operating Lease, Cost General and administrative General and Administrative Expense Type of Adoption [Domain] Accounting Standards Update [Domain] Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Renewal term of operating lease Lessee, Operating Lease, Renewal Term Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Notes payable including accrued interest Notes Payable, Current, Plus Accrued Interest Notes Payable, Current, Plus Accrued Interest License fee to be paid upon contingency License Fee, To Be Paid Upon Contingency License Fee, To Be Paid Upon Contingency Equity Component [Domain] Equity Component [Domain] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Income Statement Location Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Percentage of rights to inventions by employees under license agreement Percentage Of Rights To Inventions By Employees Under License Agreement Percentage of rights to inventions by employees under license agreement. Income Statement Location Income Statement Location [Domain] Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders' equity. Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Property and equipment, net Property, Plant and Equipment, Net ATM Sales Agreement At The Market Sales Agreement [Member] At The Market Sales Agreement [Member] Entity Tax Identification Number Entity Tax Identification Number Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Noncurrent Asset Acquisition, Contingent Consideration, Noncurrent Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Other receivables Increase (Decrease) in Other Receivables Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Remainder of 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Stockholders Equity [Table] Stockholders Equity [Table] Stockholders' equity. Other non-current assets Other Assets, Noncurrent Plan Name Plan Name [Axis] Exchange cap, percentage Common Stock, Exchange Cap, Percentage Common Stock, Exchange Cap, Percentage Issuance of common stock Stock Issued During Period, Value, New Issues Leases [Abstract] Leases [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total assets Assets Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses Operating Expenses [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Stock registered for resale (in shares) Sale of Stock, Maximum Amount Registered Sale of Stock, Maximum Amount Registered Title of 12(b) Security Title of 12(b) Security Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Weighted-average fair value of options granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value License agreement termination period due to performance failure License Agreement Termination Period Due To Performance Failure License agreement, termination period due to performance failure. Subsequent Event Type Subsequent Event Type [Axis] Antidilutive Securities Antidilutive Securities [Axis] Stockholders' equity (deficit) Stockholders' Equity Attributable to Parent [Abstract] MilanaPharm MilanaPharm [Member] MilanaPharm [Member] Class of Warrant or Right Class of Warrant or Right [Axis] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus At-the-Market Equity Offerings At-the-Market Equity Offerings [Member] At-the-Market Equity Offerings Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Deferred license revenue Contract with Customer, Liability, Noncurrent Warrants Expiring on February 15, 2023 Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Other receivables Other Receivables, Net, Current Supplemental disclosure of non-cash operating and financing activities: Supplemental Cash Flow Information [Abstract] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Upon Completion of Fifty Percent Development Not Later Than Six Months Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Less: accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Warrants Expiring on April 4, 2026 Warrants Expiring On April Four Two Thousand Twenty Six [Member] Warrants expiring on april four two thousand twenty six. Entity Filer Category Entity Filer Category Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Incremental borrowing rate Lessee, Operating Lease, Discount Rate Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Authorized amount Common Stock, Authorized Amount, Value Common Stock, Authorized Amount, Value Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Legal, accounting and other fees related to Purchase Agreement Deferred Offering Costs Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accounts payable Increase (Decrease) in Accounts Payable Issuance of common stock (in shares) Common stock, shares issued and sold Stock Issued During Period, Shares, New Issues Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Additional paid-in capital Additional Paid-in Capital [Member] Grant Award Grant Award [Text Block] Grant Award [Text Block] Working capital Working Capital Increase (Deficit) Working Capital Increase (Deficit) Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Accrued expenses Increase (Decrease) in Accrued Liabilities Non-cash adjustments reconciling net loss to operating cash flows: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock options exercised (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Offering expenses Offering Expenses Offering Expenses Loan under Paycheck Protection Program Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Employee Stock Option Stock options Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Accounting Standards Update 2017-11 Accounting Standards Update 2017-11 [Member] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Research and development Research and Development Expense Subsequent Events [Abstract] Subsequent Events [Abstract] Canceled/forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Subsequent Event Subsequent Event [Member] Sale of Stock Sale of Stock [Domain] Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Plan Name Plan Name [Domain] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Class of Stock [Axis] Class of Stock [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Weighted Average Amortization Period Weighted Average Amortization Period Weighted Average Amortization Period Income Statement [Abstract] Income Statement [Abstract] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Forgiveness of Paycheck Protection Program note payable and accrued interest Anti-dilution provision Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount Lease liabilities long-term Operating Lease, Liability, Noncurrent Accrued expenses Accrued Liabilities, Current Local Phone Number Local Phone Number Estimated fair value of warrants recorded in equity Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Lincoln Park Lincoln Park [Member] Lincoln Park Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member] Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. Non-cash operating lease cost Non-Cash Lease Expense Non-Cash Lease Expense Current assets Assets, Current [Abstract] Depreciation Depreciation Upon Delivery of Six Month Batch Development Not Later Than Eleven Months Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Project [Axis] Project [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Entity Emerging Growth Company Entity Emerging Growth Company Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Milestone payments Research And Development Milestone Payment Research and development milestone payment. Grant, Ovaprene Grant, Ovaprene [Member] Grant, Ovaprene Award Type Award Type [Axis] Forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate. Deferred grant funding Deferred Grant Funding Current Deferred Grant Funding Current Counterparty Name [Domain] Counterparty Name [Domain] Legal Entity Legal Entity [Axis] City Area Code City Area Code Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Document Period End Date Document Period End Date Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Contingent consideration, liability Business Combination, Contingent Consideration, Liability Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Accumulated deficit Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Equity Award Award Type [Domain] Number of significant performance obligations Number of Significant Performance Obligations Number of Significant Performance Obligations ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Prepaid expenses Increase (Decrease) in Prepaid Expense Trading Symbol Trading Symbol Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Exercisable (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Issuance of common stock from the exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Health Care Trust Funds [Domain] Health Care Trust Funds [Domain] Health Care Trust Funds [Domain] Health Care Trust Funds [Axis] Health Care Trust Funds [Axis] Health Care Trust Funds Note payable Notes Payable, Current Stock-based compensation Share-based Payment Arrangement, Noncash Expense Entity Entity [Domain] Net Loss Per Share Earnings Per Share [Text Block] License fees License fee License Fee License Fee Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Cover [Abstract] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Development and Option Agreement Development And Option Agreement [Member] Development And Option Agreement [Member] Current liabilities Liabilities, Current [Abstract] Upfront license fee paid Upfront License Fee Paid Upfront License Fee Paid Entity Shell Company Entity Shell Company Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Amount awarded for grant Proceeds From Award Of Grant Proceeds From Award Of Grant Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Regular purchase, common stock issuable, maximum amount (in shares) Regular Purchase, Common Stock Issuable, Maximum Amount Regular Purchase, Common Stock Issuable, Maximum Amount